138 related articles for article (PubMed ID: 20934217)
21. Poly-L-lysine-coated nanoparticles: a potent delivery system to enhance DNA vaccine efficacy.
Minigo G; Scholzen A; Tang CK; Hanley JC; Kalkanidis M; Pietersz GA; Apostolopoulos V; Plebanski M
Vaccine; 2007 Jan; 25(7):1316-27. PubMed ID: 17052812
[TBL] [Abstract][Full Text] [Related]
22. CCL19 (ELC) as an adjuvant for DNA vaccination: induction of a TH1-type T-cell response and enhancement of antitumor immunity.
Westermann J; Nguyen-Hoai T; Baldenhofer G; Höpken UE; Lipp M; Dörken B; Pezzutto A
Cancer Gene Ther; 2007 Jun; 14(6):523-32. PubMed ID: 17384577
[TBL] [Abstract][Full Text] [Related]
23. Nonspecific CD4(+) T cells with uptake of antigen-specific dendritic cell-released exosomes stimulate antigen-specific CD8(+) CTL responses and long-term T cell memory.
Hao S; Yuan J; Xiang J
J Leukoc Biol; 2007 Oct; 82(4):829-38. PubMed ID: 17626150
[TBL] [Abstract][Full Text] [Related]
24. Polarized immune responses modulated by layered double hydroxides nanoparticle conjugated with CpG.
Yan S; Rolfe BE; Zhang B; Mohammed YH; Gu W; Xu ZP
Biomaterials; 2014 Nov; 35(35):9508-16. PubMed ID: 25145853
[TBL] [Abstract][Full Text] [Related]
25. Enhanced immune response to the melanoma antigen gp100 using recombinant adenovirus-transduced dendritic cells.
Wan Y; Emtage P; Zhu Q; Foley R; Pilon A; Roberts B; Gauldie J
Cell Immunol; 1999 Dec; 198(2):131-8. PubMed ID: 10648127
[TBL] [Abstract][Full Text] [Related]
26. Improved efficacy of DNA vaccination against prostate carcinoma by boosting with recombinant protein vaccine and by introduction of a novel adjuvant epitope.
Lu Y; Ouyang K; Fang J; Zhang H; Wu G; Ma Y; Zhang Y; Hu X; Jin L; Cao R; Fan H; Li T; Liu J
Vaccine; 2009 Aug; 27(39):5411-8. PubMed ID: 19616501
[TBL] [Abstract][Full Text] [Related]
27. Delivery of noncarrier naked DNA vaccine into the skin by supersonic flow induces a polarized T helper type 1 immune response to cancer.
Lin CC; Yen MC; Lin CM; Huang SS; Yang HJ; Chow NH; Lai MD
J Gene Med; 2008 Jun; 10(6):679-89. PubMed ID: 18324638
[TBL] [Abstract][Full Text] [Related]
28. Novel chitosan derivative nanoparticles enhance the immunogenicity of a DNA vaccine encoding hepatitis B virus core antigen in mice.
Jiang L; Qian F; He X; Wang F; Ren D; He Y; Li K; Sun S; Yin C
J Gene Med; 2007 Apr; 9(4):253-64. PubMed ID: 17397104
[TBL] [Abstract][Full Text] [Related]
29. Injection site-dependent induction of immune response by DNA vaccine: comparison of skin and spleen as a target for vaccination.
Guan X; Nishikawa M; Takemoto S; Ohno Y; Yata T; Takakura Y
J Gene Med; 2010 Mar; 12(3):301-9. PubMed ID: 20084616
[TBL] [Abstract][Full Text] [Related]
30. Engineering enhancement of the immune response to HBV DNA vaccine in mice by the use of LIGHT gene adjuvant.
Zhang Y; Jiang W; Fan Y; Wen J; Hao W; Qian M
J Virol Methods; 2008 Nov; 153(2):142-8. PubMed ID: 18722475
[TBL] [Abstract][Full Text] [Related]
31. Augmentation of the migratory ability of DC-based vaccine into regional lymph nodes by efficient CCR7 gene transduction.
Okada N; Mori N; Koretomo R; Okada Y; Nakayama T; Yoshie O; Mizuguchi H; Hayakawa T; Nakagawa S; Mayumi T; Fujita T; Yamamoto A
Gene Ther; 2005 Jan; 12(2):129-39. PubMed ID: 15483669
[TBL] [Abstract][Full Text] [Related]
32. High adjuvant activity of layered double hydroxide nanoparticles and nanosheets in anti-tumour vaccine formulations.
Yan S; Gu W; Zhang B; Rolfe BE; Xu ZP
Dalton Trans; 2018 Feb; 47(9):2956-2964. PubMed ID: 29168855
[TBL] [Abstract][Full Text] [Related]
33. Enhancement of cellular immune response to a prostate cancer DNA vaccine by intradermal electroporation.
Roos AK; Moreno S; Leder C; Pavlenko M; King A; Pisa P
Mol Ther; 2006 Feb; 13(2):320-7. PubMed ID: 16185933
[TBL] [Abstract][Full Text] [Related]
34. Dendritic cells engineered to express the Flt3 ligand stimulate type I immune response, and induce enhanced cytoxic T and natural killer cell cytotoxicities and antitumor immunity.
Liu Y; Huang H; Chen Z; Zong L; Xiang J
J Gene Med; 2003 Aug; 5(8):668-80. PubMed ID: 12898636
[TBL] [Abstract][Full Text] [Related]
35. Shielding the cationic charge of nanoparticle-formulated dermal DNA vaccines is essential for antigen expression and immunogenicity.
van den Berg JH; Oosterhuis K; Hennink WE; Storm G; van der Aa LJ; Engbersen JF; Haanen JB; Beijnen JH; Schumacher TN; Nuijen B
J Control Release; 2010 Jan; 141(2):234-40. PubMed ID: 19751778
[TBL] [Abstract][Full Text] [Related]
36. Development of a novel Hsp70-based DNA vaccine as a multifunctional antigen delivery system.
Yamaoka A; Guan X; Takemoto S; Nishikawa M; Takakura Y
J Control Release; 2010 Mar; 142(3):411-5. PubMed ID: 19913062
[TBL] [Abstract][Full Text] [Related]
37. Vaccination with a DNA vaccine based on human PSCA and HSP70 adjuvant enhances the antigen-specific CD8+ T-cell response and inhibits the PSCA+ tumors growth in mice.
Zhang X; Yu C; Zhao J; Fu L; Yi S; Liu S; Yu T; Chen W
J Gene Med; 2007 Aug; 9(8):715-26. PubMed ID: 17595048
[TBL] [Abstract][Full Text] [Related]
38. Gene-modified tumor vaccine with therapeutic potential shifts tumor-specific T cell response from a type 2 to a type 1 cytokine profile.
Hu HM; Urba WJ; Fox BA
J Immunol; 1998 Sep; 161(6):3033-41. PubMed ID: 9743368
[TBL] [Abstract][Full Text] [Related]
39. [The mechanism of anti-tumor immune response against mouse melanoma to xenogeneic vaccination].
Luo F; Mao YQ; Kan B; He QM; Jiang Y; Peng F; Yang L; Tian L
Sichuan Da Xue Xue Bao Yi Xue Ban; 2004 Nov; 35(6):757-60. PubMed ID: 15573746
[TBL] [Abstract][Full Text] [Related]
40. Potentiation of immunologic responsiveness to dendritic cell-based tumor vaccines by recombinant interleukin-2.
Shimizu K; Fields RC; Redman BG; Giedlin M; Mulé JJ
Cancer J Sci Am; 2000 Feb; 6 Suppl 1():S67-75. PubMed ID: 10685663
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
